Sökning: WFRF:(Ardissino Diego)
> (2015-2019) >
Clinically signific...
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1) : a double-blind, multicentre, randomised trial
-
- Ohman, E. Magnus (författare)
- Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
-
- Roe, Matthew T. (författare)
- Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
-
- Steg, P. Gabriel (författare)
- Univ Paris Diderot, AP HP, DHU FIRE, Paris, France.;INSERM, U1148, Paris, France.;Imperial Coll London, NHLI Royal Brompton Hosp, London, England.
-
visa fler...
-
- James, Stefan K., 1964- (författare)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
- Povsic, Thomas J. (författare)
- Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
-
- White, Jennifer (författare)
- Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
-
- Rockhold, Frank (författare)
- Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
-
- Plotnikov, Alexei (författare)
- Janssen Res & Dev, Raritan, NJ USA.
-
- Mundl, Hardi (författare)
- Bayer AG, Wuppertal, Germany.
-
- Strony, John (författare)
- Janssen Res & Dev, Raritan, NJ USA.
-
- Sun, Xiang (författare)
- Janssen Res & Dev, Raritan, NJ USA.
-
- Husted, Steen (författare)
- Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark.
-
- Tendera, Michal (författare)
- Med Univ Silesia, Div Cardiol 3, Katowice, Poland.
-
- Montalescot, Gilles (författare)
- Grp Hosp Pitie Salpetriere, Inst Cardiol, Paris, France.
-
- Cecilia Bahit, M. (författare)
- INECO Neurociencias Orono, Rosario, Santa Fe, Argentina.
-
- Ardissino, Diego (författare)
- Policlin San Matteo, Div Cardiol, Pavia, Italy.
-
- Bueno, Hector (författare)
- Spanish Natl Ctr Cardiovasc Res, Madrid, Spain.
-
- Claeys, Marc J. (författare)
- Univ Antwerp Hosp, Edegem, Belgium.
-
- Nicolau, Jose C. (författare)
- Univ Sao Paulo, Med Sch, Heart Inst InCor, Sao Paulo, Brazil.
-
- Cornel, Jan H. (författare)
- Noordwest Ziekenhuisgrp Alkmaar & Dutch Network C, Dept Cardiol, Alkmaar, Netherlands.
-
- Goto, Shinya (författare)
- Tokai Univ, Sch Med, Dept Med Cardiol, Isehara, Kanagawa, Japan.
-
- Kiss, Robert Gabor (författare)
- Mil Hosp, Dept Cardiol, Budapest, Hungary.
-
- Guray, Umit (författare)
- Numune Educ & Res Hosp, Dept Cardiol, Ankara, Turkey.
-
- Park, Duk-Woo (författare)
- Univ Ulsan, Coll Med, Asan Med Ctr, Div Cardiol, Seoul, South Korea.
-
- Bode, Christoph (författare)
- Univ Freiberg, Freiburg, Germany.
-
- Welsh, Robert C. (författare)
- Mazankowski Alberta Heart Inst, Edmonton, AB, Canada.;Univ Alberta, Edmonton, AB, Canada.
-
- Gibson, C. Michael (författare)
- Harvard Med Sch, Beth Israel Deaconess Hosp, PERFUSE Study Grp, Boston, MA USA.
-
visa färre...
-
Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA Univ Paris Diderot, AP HP, DHU FIRE, Paris, France.;INSERM, U1148, Paris, France.;Imperial Coll London, NHLI Royal Brompton Hosp, London, England. (creator_code:org_t)
- 2017
- 2017
- Engelska.
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 389:10081, s. 1799-1808
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increased bleeding. The safety of a dual pathway antithrombotic therapy approach combining low-dose rivaroxaban (in place of aspirin) with a P2Y12 inhibitor has not been assesssed in acute coronary syndromes. We aimed to assess rivaroxaban 2.5 mg twice daily versus aspirin 100 mg daily, in addition to clopidogrel or ticagrelor (chosen at investigator discretion before randomisation), for patients with acute coronary syndromes started within 10 days after presentation and continued for 6-12 months.Methods In this double-blind, multicentre, randomised trial (GEMINI-ACS-1) done at 371 clinical centres in 21 countries, eligible patients were older than 18 years with unstable angina, non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI), with positive cardiac biomarkers and either ischaemic electrocardiographic changes or an atherosclerotic culprit lesion identified during angiography. Participants were randomly assigned (1: 1) within 10 days after admission for the index acute coronary syndromes event to either aspirin or rivaroxaban based on a computer-generated randomisation schedule. Randomisation was balanced by using randomly permuted blocks with size of four and was stratified based on the background P2Y12 inhibitor (clopidogrel or ticagrelor) intended to be used at the time of randomisation. Investigators and patients were masked to treatment assignment. Patients received a minimum of 180 days of double-blind treatment with rivaroxaban 2.5 mg twice daily or aspirin 100 mg daily. The choice of clopidogrel or ticagrelor during trial conduct was not randomised and was based on investigator preference. The primary endpoint was thrombolysis in myocardial infarction (TIMI) clinically significant bleeding not related to coronary artery bypass grafting (CABG; major, minor, or requiring medical attention) up to day 390. Primary analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT02293395.Findings Between April 22, 2015, and Oct 14, 2016, 3037 patients with acute coronary syndromes were randomly assigned; 1518 to receive aspirin and 1519 to receive rivaroxaban. 1704 patients (56%) were in the ticagrelor and 1333 (44%) in the clopidogrel strata. Median duration of treatment was 291 days (IQR 239-354). TIMI non-CABG clinically significant bleeding was similar with rivaroxaban versus aspirin therapy (total 154 patients [5%]; 80 participants [5%] of 1519 vs 74 participants [5%] of 1518; HR 1.09 [95% CI 0.80-1.50]; p=0.5840).Interpretation A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor. A larger, adequately powered trial would be required to definitively assess the efficacy and safety of this approach.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ohman, E. Magnus
-
Roe, Matthew T.
-
Steg, P. Gabriel
-
James, Stefan K. ...
-
Povsic, Thomas J ...
-
White, Jennifer
-
visa fler...
-
Rockhold, Frank
-
Plotnikov, Alexe ...
-
Mundl, Hardi
-
Strony, John
-
Sun, Xiang
-
Husted, Steen
-
Tendera, Michal
-
Montalescot, Gil ...
-
Cecilia Bahit, M ...
-
Ardissino, Diego
-
Bueno, Hector
-
Claeys, Marc J.
-
Nicolau, Jose C.
-
Cornel, Jan H.
-
Goto, Shinya
-
Kiss, Robert Gab ...
-
Guray, Umit
-
Park, Duk-Woo
-
Bode, Christoph
-
Welsh, Robert C.
-
Gibson, C. Micha ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
The Lancet
- Av lärosätet
-
Uppsala universitet